نتایج جستجو برای: 213bi

تعداد نتایج: 97  

Journal: :Cancer control : journal of the Moffitt Cancer Center 2002
John M Burke Joseph G Jurcic David A Scheinberg

BACKGROUND The use of monoclonal antibodies to deliver radioactive isotopes directly to tumor cells has become a promising strategy to enhance the antitumor effects of native monoclonal antibodies. In this article, we summarize the role of radioimmunotherapy in the treatment of leukemia. METHODS The authors reviewed the published clinical trials of radioimmunotherapy in acute leukemia. RESU...

2004
Deborah A. Mulford

The use of monoclonal antibodies to deliver radioisotopes directly to tumor cells has become a promising strategy to enhance the antitumor effects of native antibodies. Since the and -particles emitted during the decay of radioisotopes differ in significant ways, proper selection of isotope and antibody combinations is crucial to making radioimmunotherapy a standard therapeutic modality. Becaus...

2013
Christian Wulbrand Christof Seidl Florian C. Gaertner Frank Bruchertseifer Alfred Morgenstern Markus Essler Reingard Senekowitsch-Schmidtke

Hypoxia is a central problem in tumor treatment because hypoxic cells are less sensitive to chemo- and radiotherapy than normoxic cells. Radioresistance of hypoxic tumor cells is due to reduced sensitivity towards low Linear Energy Transfer (LET) radiation. High LET α-emitters are thought to eradicate tumor cells independent of cellular oxygenation. Therefore, the aim of this study was to demon...

2016
Ho Sze Chan Mark W. Konijnenberg Erik de Blois Stuart Koelewijn Richard P. Baum Alfred Morgenstern Frank Bruchertseifer Wouter A. Breeman Marion de Jong

BACKGROUND Targeted alpha therapy has been postulated to have great potential for the treatment of small clusters of tumour cells as well as small metastases. (213)Bismuth, an α-emitter with a half-life of 46 min, has shown to be effective in preclinical as well as in clinical applications. In this study, we evaluated whether (213)Bi-[DOTA(0), Tyr(3)]-octreotate ((213)Bi-DOTATATE), a (213)Bi-la...

Journal: :Cancer biotherapy & radiopharmaceuticals 2017
Ekaterina Revskaya Zewei Jiang Alfred Morgenstern Frank Bruchertseifer Muctarr Sesay Susan Walker Steven Fuller Michael S Lebowitz Claudia Gravekamp Hossein A Ghanbari Ekaterina Dadachova

There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully...

2016
Takahiro Yoshida Kideok Jin Hong Song Sunju Park David L. Huso Zhe Zhang Han Liangfeng Charles Zhu Frank Bruchertseifer Alfred Morgenstern George Sgouros Saraswati Sukumar

The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of ra...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید